A. Forner, M. Reig, J. Bruix, and . Hepatocellular, Lancet, vol.391, issue.3, pp.1301-1315, 2018.

I. Rosa, J. Denis, R. P. Lesgourgues, B. Dobrin, A. S. Becker et al., 585 A French multicentric longitudinal descriptive study of hepatocellular carcinoma management (the Changh cohort): preliminary results, Journal of Hepatology, vol.52, issue.4, pp.231-263, 2010.

V. W. Keng, D. A. Largaespada, and A. Villanueva, Why men are at higher risk for hepatocellular carcinoma?, J Hepatol, vol.57, issue.2, pp.453-54, 2012.

M. Chang, S. You, and C. Chen, Long-term effects of hepatitis B immunization of infants in preventing liver cancer, Gastroenterology, vol.151, issue.3, pp.472-80, 2016.

A. K. Singal, A. Singh, and S. Jaganmohan, Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis, Clin Gastroenterol Hepatol, vol.8, issue.2, pp.192-99, 2010.

G. N. Ioannou, L. A. Beste, P. K. Green, A. G. Singal, E. B. Tapper et al., Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores, Gastroenterology, vol.157, issue.5, pp.1264-78, 2019.

, International Consensus Group for Hepatocellular, Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia, Hepatology, vol.49, issue.2, pp.658-64, 2009.

M. Borzio, S. Fargion, F. Borzio, A. L. Fracanzani, A. M. Croce et al., Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development, Journal of Hepatology, vol.39, issue.2, pp.208-222, 2003.

T. M. Pawlik, K. A. Delman, J. Vauthey, D. M. Nagorney, I. Ng et al., Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma, Liver Transplantation, vol.11, issue.9, pp.1086-92, 2005.

E. S. Bialecki, D. Bisceglie, and A. M. , Diagnosis of hepatocellular carcinoma, HPB (Oxford), vol.7, issue.1, pp.26-34, 2005.

J. Bruix, A. Castells, X. Calvet, F. Feu, C. Bru et al., Diarrhea as a presenting symptom of hepatocellular carcinoma, Dig Dis Sci. juin, vol.35, issue.6, pp.681-85, 1990.

L. Schwarz, M. Bubenheim, J. Zemour, A. Herrero, F. Muscari et al., Bleeding Recurrence and Mortality Following Interventional Management of Spontaneous HCC Rupture: Results of a Multicenter European Study, World J Surg, vol.42, issue.1, pp.225-257, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02349576

J. Luo, S. Hwang, J. Wu, C. Lai, C. Li et al., Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes, Hepatogastroenterology, vol.49, issue.47, pp.1315-1334, 2002.

M. Si, F. Amersi, S. R. Golish, J. A. Ortiz, J. Zaky et al., Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival, Am Surg, vol.69, issue.10, pp.879-85, 2003.

, EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma, J Hepatol, vol.69, issue.1, pp.182-236, 2018.

C. Aubé, F. Oberti, J. Lonjon, G. Pageaux, O. Seror et al., EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice, Liver Int, vol.37, issue.10, pp.1515-1540, 2017.

A. Forner, R. Vilana, C. Ayuso, L. Bianchi, M. Sole et al., Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, Hepatology, vol.47, issue.1, pp.97-104, 2008.

S. Diagnosis, . Management-of-hepatocellular, and . Carcinoma, Hepatology, vol.68, issue.2, pp.723-50, 2018.

Y. J. Lee, J. M. Lee, J. S. Lee, H. Y. Lee, B. H. Park et al., Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis, Radiology, vol.275, issue.1, pp.97-109, 2015.

J. Guo, Y. Seo, S. Ren, S. Hong, D. Lee et al., Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis, Abdom Radiol, vol.41, issue.1, pp.1960-72, 2016.

A. Luciani, Séquences de diffusion et produits de contraste hépatobiliaires en IRM du foie : les évolutions en cours, 2017.

D. G. Mitchell, J. Bruix, M. Sherman, C. B. Sirlin, and . Li-rads, Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions, Hepatology, vol.61, issue.3, pp.1056-65, 2015.

A. R. Reynolds, A. Furlan, D. T. Fetzer, E. Sasatomi, A. A. Borhani et al., Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know, RadioGraphics, vol.35, issue.2, pp.371-86, 2015.

M. Kanematsu, R. C. Semelka, P. Leonardou, M. Mastropasqua, and J. K. Lee, Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations, J Magn Reson Imaging, vol.18, issue.2, pp.189-95, 2003.

J. Schölmerich and D. Schacherer, Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport?, Gut, vol.53, issue.9, pp.1224-1250, 2004.

S. Leoni, F. Piscaglia, R. Golfieri, V. Camaggi, G. Vidili et al., The impact of vascular and non vascular findings on the noninvasive diagnosis of small hepatocarcinoma based on the EASL and AASLD criteria, AM J Gastroenterol, vol.105, issue.3, pp.599-609, 2010.

E. Caturelli, E. Biasini, F. Bartolucci, D. Facciorusso, F. Decembrino et al., Diagnosis of hepatocellular carcinoma complicating liver cirrhosis: utility of repeat ultrasound-guided biopsy after unsuccessful first sampling, Cardiovasc Intervent Radiol, vol.25, issue.4, pp.295-304, 2002.

S. Tremosini, A. Forner, and L. Boix, Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma, Gut, vol.61, issue.10, pp.1481-87, 2012.

X. Adhoute, G. Penaranda, P. Castellani, H. Perrier, and M. Bourliere, Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?, World J Hepatol, vol.7, issue.3, pp.521-552, 2015.

J. M. Llovet, C. Brú, and J. Bruix, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, vol.19, issue.3, pp.329-367, 1999.

B. F. Crandall, Alpha-fetoprotein: a review, Crit Rev Clin Lab Sci, vol.15, issue.2, pp.127-85, 1981.

A. Abbasi, A. R. Bhutto, N. Butt, and S. M. Munir, Correlation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma, J Pak Med Assoc, vol.62, issue.1, pp.33-36, 2012.

P. P. Mchugh, J. Gilbert, S. Vera, A. Koch, D. Ranjan et al., Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma, HPB, vol.12, issue.1, pp.56-61, 2010.

T. Okusaka, S. Okada, H. Ueno, M. Ikeda, K. Shimada et al., Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features, Cancer, vol.95, issue.9, pp.1931-1968, 2002.

C. Duvoux, Liver transplantation for hepatocellular carcinoma: a model including ?-fetoprotein improves the performance of Milan criteria, Gastroenterology, vol.143, issue.4, pp.986-94, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00865368

S. Savastano, D. Miotto, and G. Casarrubea, Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors, J Clin Gastroenterol, vol.28, issue.4, pp.334-374, 1999.

G. Liu, Q. Ouyang, F. Xia, G. Fan, J. Yu et al., Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma, HPB (Oxford), vol.21, issue.1, pp.107-120, 2019.

. Wang, Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization, Ann Surg Oncol, vol.19, issue.11, pp.3540-3546, 2012.

G. Han, S. Berhane, H. Toyoda, D. Bettinger, O. Elshaarawy et al., Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach, Hepatology, 2019.

N. Mehta, N. Fidelman, M. Sarkar, and F. Y. Yao, Factors Associated With Outcomes and Response to Therapy in Patients With Infiltrative Hepatocellular Carcinoma, Clinical Gastroenterology and Hepatology, vol.11, issue.5, pp.572-78, 2013.

X. Adhoute, G. Pénaranda, J. L. Raoul, J. F. Blanc, E. J. Conroy et al., Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study, Eur J Gastroenterol Hepatol, vol.28, issue.4, pp.433-473, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01310454

T. Yau, V. Tang, T. Yao, S. Fan, C. Lo et al., Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma, Gastroenterology, vol.146, issue.7, pp.1691-1700, 2014.

R. Lencioni, P. Petruzzi, and L. Crocetti, Chemoembolization of Hepatocellular Carcinoma, Semin Intervent Radiol, vol.30, issue.1, pp.3-11, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01134844

R. Lencioni, T. De-baere, M. C. Soulen, W. S. Rilling, and J. Geschwind, Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data, Hepatology, vol.64, issue.1, pp.106-122, 2016.

. Bouvier, Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival, Eur Radiol, vol.21, issue.8, pp.1719-1745, 2011.

K. Ahrar and S. Gupta, Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes, Surg Oncol Clin N Am, vol.12, issue.1, pp.105-131, 2003.

R. Golfieri, E. Giampalma, M. Renzulli, R. Cioni, I. Bargellini et al., Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma, Br J Cancer, vol.111, issue.2, pp.255-64, 2014.

L. Bolondi, A. Burroughs, J. Dufour, P. R. Galle, V. Mazzaferro et al., Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions, Semin Liver Dis, vol.32, issue.4, pp.348-59, 2012.

I. Waked, S. Berhane, H. Toyoda, S. L. Chan, N. Stern et al., Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion, Br J Cancer, vol.116, issue.4, pp.448-54, 2017.

M. Moriguchi, M. Furuta, and Y. Itoh, A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus, Journal of Clinical and Translational Hepatology, vol.5, issue.2, pp.177-83, 2017.

G. Millonig, I. W. Graziadei, M. C. Freund, W. Jaschke, S. Stadlmann et al., Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma, Liver Transplantation, vol.13, issue.2, pp.272-79, 2007.

W. D. Luna, D. Y. Sze, A. Ahmed, B. Y. Ha, W. Ayoub et al., Transarterial Chemoinfusion for Hepatocellular Carcinoma as Downstaging Therapy and a Bridge toward Liver Transplantation, American Journal of Transplantation, vol.9, issue.5, pp.1158-68, 2009.

G. Millonig, I. W. Graziadei, M. C. Freund, W. Jaschke, S. Stadlmann et al., Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma, Liver Transplantation, vol.13, issue.2, pp.272-79, 2007.

J. Park, M. Chen, M. Colombo, L. R. Roberts, M. Schwartz et al., Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study, Liver International, vol.35, issue.9, pp.2155-66, 2015.

M. Peck-radosavljevic, M. Kudo, J. Raoul, H. C. Lee, T. Decaens et al., Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis, JCO, vol.36, issue.15_suppl, p.4018, 2018.

L. Kadalayil, R. Benini, L. Pallan, J. O'beirne, L. Marelli et al., A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer, Ann Oncol, vol.24, issue.10, pp.2565-70, 2013.

D. J. Pinato, T. Arizumi, E. Allara, J. W. Jang, C. Smirne et al., Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification, Clin Gastroenterol Hepatol, vol.13, issue.6, pp.1204-1212, 2015.

Y. Park, S. U. Kim, B. K. Kim, J. Y. Park, D. Y. Kim et al., Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score, Liver Int, vol.36, issue.1, pp.100-107, 2016.

A. Cappelli, A. Cucchetti, and G. Cabibbo, Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma, Liver Int, vol.36, issue.5, pp.729-765, 2016.

J. Hansmann, M. J. Evers, J. T. Bui, R. P. Lokken, A. J. Lipnik et al., Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma, J Vasc Interv Radiol, vol.28, issue.9, pp.1224-1255, 2017.

X. Adhoute, G. Pénaranda, J. L. Raoul, E. Bollon, B. Pol et al., NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization, Eur J Gastroenterol Hepatol, vol.29, issue.6, pp.706-721, 2017.

T. Su, S. Liao, C. Hong, C. Liu, T. Tseng et al., NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging, J Gastroenterol Hepatol, 2019.

F. Hucke, M. Pinter, I. Graziadei, S. Bota, W. Vogel et al., How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma, J Hepatol, vol.61, issue.6, pp.1287-96, 2014.

V. Mazzaferro, J. M. Llovet, R. Miceli, S. Bhoori, M. Schiavo et al., Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol, vol.10, issue.1, pp.35-43, 2009.

C. Georgiades, J. F. Geschwind, N. Harrison, A. Hines-peralta, E. Liapi et al., Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment?, Radiology, vol.265, issue.1, pp.115-138, 2012.

W. Sieghart, F. Hucke, M. Pinter, I. Graziadei, W. Vogel et al., The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma, Hepatology, vol.57, issue.6, pp.2261-73, 2013.

F. Hucke, W. Sieghart, M. Pinter, I. Graziadei, W. Vogel et al., The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE, J Hepatol, vol.60, issue.1, pp.118-144, 2014.

E. Terzi, L. Terenzi, L. Venerandi, L. Croci, M. Renzulli et al., The ART Score Is Not Effective to Select Patients for Transarterial Chemoembolization Retreatment in an Italian Series, Dig Dis, vol.32, issue.6, pp.711-727, 2014.

C. Tseng, W. Lai, C. Huang, Y. Huang, C. Su et al., The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment, Medicine (Baltimore), vol.94, issue.47, p.1659, 2015.

X. Adhoute, G. Penaranda, S. Naude, J. L. Raoul, H. Perrier et al., Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process, Journal of Hepatology, vol.62, issue.4, pp.855-62, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01684541

R. Kloeckner, M. B. Pitton, C. Dueber, I. Schmidtmann, P. R. Galle et al., Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma, J Vasc Interv Radiol. janv, vol.28, issue.1, pp.94-102, 2017.

. Adhoute, utilité des scores pronostiques dans le carcinome hépatocellulaire, Hepato-gastro et oncologie digestive. 2016, vol.23

R. Golfieri, M. Renzulli, C. Mosconi, L. Forlani, E. Giampalma et al., Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?, J Vasc Interv Radiol. avr, vol.24, issue.4, pp.509-526, 2013.

A. Forner, C. Ayuso, M. Varela, J. Rimola, A. J. Hessheimer et al., Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer, vol.115, pp.616-639, 2009.

I. Bargellini, E. Bozzi, D. Campani, P. Carrai, D. Simone et al., Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants, Eur J Radiol, vol.82, issue.5, pp.212-230, 2013.

J. Bruix, M. Sherman, J. M. Llovet, M. Beaugrand, R. Lencioni et al., Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J Hepatol, vol.35, issue.3, pp.421-451, 2001.

E. S. Jung, J. H. Kim, E. L. Yoon, H. J. Lee, S. J. Lee et al., Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization, J Hepatol, vol.58, issue.6, pp.1181-87, 2013.

R. Gillmore, S. Stuart, A. Kirkwood, A. Hameeduddin, N. Woodward et al., EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization, J Hepatol, vol.55, issue.6, pp.1309-1325, 2011.

. Cederholm, ESPEN guidelines on definitions and terminology of clinical nutrition, Clinical Nutrition, vol.36, issue.1, pp.49-64, 2018.

. Merli, Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi, Hepatology, vol.23, issue.5, pp.1041-1087, 1996.

. Maharshi, Malnutrition in cirrhosis increases morbidity and mortality, J Gastroenterol Hepatol, vol.30, issue.10, pp.1507-1520, 2015.

, Nutritional indices in cirrhotic patients, Nutrition, vol.22, issue.2, pp.216-233, 2006.

. Plauth, ESPEN guideline on clinical nutrition in liver disease, Clinical Nutrition, vol.38, issue.2, pp.485-521, 2019.

C. Jentoft, Sarcopenia: revised European consensus on definition and diagnosis, vol.48, pp.16-31, 2018.

. Tandon, Severe muscle depletion in patients on the liver transplantation wait list: its prevalence and independent prognosis value, Liver Transplantation, vol.18, issue.10, pp.1209-1225, 2012.

. Carey, A multicenter study to define sarcopenia in patients with end-stage liver disease, Liver Transpl, vol.23, issue.5, pp.625-658, 2017.

. Cederholm, GLIM criteria for the diagnosis of malnutrition : A consensus report from the global clinical nutrition community, Clin Nutr, vol.38, issue.1, pp.1-9, 2018.

. Daphnee, Hand grip strength: A reliable, reproducible, cost-effective tool to assess the nutritional status and outcomes of cirrhotics awaiting liver transplant, Clin Nutr, vol.19, issue.6, pp.49-53

. Sinclair, Handgrip Strength adds more prognostic value to the Model for End-Stage Liver Disease score than imaging-based measures of muscle mass in men with cirrhosis, Liver Transplant, vol.25, issue.10, pp.1480-87, 2019.

. Mourtzakis, A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Appl Physiol Nutr Metab, vol.33, pp.997-1006, 2008.

M. Merli, A. Berzigotti, S. Zelber-sagi, S. Dasarathy, S. Montagnese et al., EASL Clinical Practice Guidelines on nutrition in chronic liver disease, Journal of Hepatology, vol.70, issue.1, pp.172-93, 2019.

E. J. Carey, J. C. Lai, C. Sonnenday, E. B. Tapper, P. Tandon et al., A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation, Hepatology, vol.70, issue.5, pp.1816-1845, 2019.

P. Begini, E. Gigante, G. Antonelli, F. Carbonetti, E. Iannicelli et al., Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis, Ann Hepatol, vol.16, issue.1, pp.107-121, 2017.

K. Imai, K. Takai, T. Hanai, T. Ideta, T. Miyazaki et al., Skeletal Muscle Depletion Predicts the Prognosis of Patients with Hepatocellular Carcinoma Treated with Sorafenib, Int J Mol Sci. 28 avr, vol.16, issue.5, pp.9612-9636, 2015.

. Fujiwara, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma, J Hepatol, vol.63, issue.1, pp.131-171, 2015.

R. M. Dodson, A. Firoozmand, O. Hyder, V. Tacher, D. P. Cosgrove et al., Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies, J Gastrointest Surg, vol.17, issue.12, pp.2123-2155, 2013.

. Durand, Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography, J Hepatol, vol.60, issue.6, pp.1151-57, 2014.

. Ebadi, Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis, Journal of Cachexia, Sarcopenia and Muscle, vol.9, pp.1053-62, 2018.

R. Ciria, P. López-cillero, A. Gallardo, J. Cabrera, M. Pleguezuelo et al., Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization, European Journal of Surgical Oncology, vol.41, issue.9, pp.1153-61, 2015.

J. Raoul, M. Gilabert, and X. Adhoute, To TACE or not to TACE? Lessons from a negative trial, The Lancet Gastroenterology & Hepatology, vol.2, issue.8, pp.541-584, 2017.

K. Katayama, T. Imai, and Y. Abe, Number of nodules but not size of hepatocellular carcinoma can predict refractoriness to transarterial chemoembolization and poor prognosis, J Clin Med Res, vol.10, issue.1, pp.765-71, 2018.

Q. Wang, D. Xia, W. Bai, W. E. Sun, J. Huang et al., Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study, J Hepatol, vol.70, issue.5, pp.893-903, 2019.

J. W. Chung, J. H. Park, and J. K. Han, Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization, Radiology, vol.198, issue.1, pp.33-40, 1996.

F. Piscaglia, E. Terzi, A. Cucchetti, C. Trimarchi, A. Granito et al., Treatment of hepatocellular carcinoma in Child-Pugh B patients, Dig Liver Dis, vol.45, issue.10, pp.852-58, 2013.

D. J. Pinato, R. Sharma, E. Allara, C. Yen, T. Arizumi et al., The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma, J Hepatol, vol.66, issue.2, pp.338-384, 2017.

P. Tandon and G. Garcia-tsao, Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies, Liver Int, vol.29, issue.4, pp.502-512, 2008.

T. Hashimoto, H. Nakamura, S. Hori, K. Tomoda, K. Nakanishi et al., Hepatocellular carcinoma: efficacy of transcatheter oily chemoembolization in relation to macroscopic and microscopic patterns of tumor growth among 100 patients with partial hepatectomy, Cardiovasc Intervent Radiol. avr, vol.18, issue.2, pp.82-88, 1995.

M. Renzulli, S. Brocchi, A. Cucchetti, F. Mazzotti, C. Mosconi et al., Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma?, Radiology. 10 déc, vol.279, issue.2, pp.432-474, 2015.

E. S. Jang, J. Yoon, J. W. Chung, E. J. Cho, S. J. Yu et al., Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization, J Cancer Res Clin Oncol, vol.139, issue.4, pp.635-678, 2013.

J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, vol.359, issue.4, pp.378-90, 2008.
URL : https://hal.archives-ouvertes.fr/hal-02927464

M. Pinter, F. Hucke, I. Graziadei, W. Vogel, A. Maieron et al., Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib, Radiology, vol.263, issue.2, pp.590-99, 2012.

D. Yoo, K. M. Kim, Y. Jin, J. H. Shim, G. Ko et al., Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?, J Gastroenterol Hepatol, vol.26, issue.1, pp.145-54, 2011.

. Wang, A Comparison of Muscle Function, Mass, and Quality in Liver Transplant Candidates, Transplantation, vol.100, issue.8, pp.1692-98, 2016.

C. G. Child and J. G. Turcotte, Surgery and Portal Hypertension, The Liver and Portal Hypertension, pp.50-64, 1964.

. Serment-d'hippocrate,

, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

. Serment-d'hippocrate,

, En présence des Maîtres de cette FACULTE et de mes chers CONDISCIPLES, je promets et je jure d'être fidèle aux lois de l'Honneur et de la Probité dans l'exercice de la Médecine

, Admis dans l'intérieur des maisons, mes yeux ne verront pas ce qui s'y passe, ma langue taira les secrets qui me seront confiés et mon état ne servira pas à corrompre les moeursni à favoriser le crime

, Respectueux et reconnaissant envers mes MAÎTRES, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères

, Que les HOMMES m'accordent leur estime si je suis fidèle à mes promesses. Que je sois couvert d'OPPROBRE et méprisé de mes confrères si j'y manque